Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inhibrx LLC

Latest From Inhibrx LLC

Deal Watch: Cancer Remains Hot Target At J.P. Morgan

Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.

Cancer Commercial

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

Science Matters: CD47 Pathway Links To CV Disease, New Drug Development Opportunities

Initial research about inhibiting CD47 signaling on tumor cells has meant a focus on oncology drug development. New research shows that inhibiting this cell surface molecule could be used to treat atherosclerosis.

Cardiovascular Research & Development

Forty Seven Raises $75 Million For Possible 'Universal' Cancer Therapy

Forty Seven Inc. spun out of Stanford with a $75 million Series A and an immuno-oncology development program that's already in the clinic with data expected later this year.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Inhibrx LLC
  • Senior Management
  • Mark Lappe, CEO
    Quinn Deveraux, PhD, VP, R&D
  • Contact Info
  • Inhibrx LLC
    Phone: (858) 759-1499
    11099 N. Torrey Pines Rd.
    Ste. 280
    La Jolla, CA 92037